Alzheimers Disease Drug Market Report 2023 (Global Edition)

Global Alzheimers Disease Drug Market Report 2023 talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Alzheimers Disease Drug Industry growth. Alzheimers Disease Drug market has been segmented with the help of its Type, Application Type of Disease, and others. Alzheimers Disease Drug market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.

Report scope is customizable as we have a huge database of Alzheimers Disease Drug industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.

Type Segment Analysis of Alzheimers Disease Drug Market

Based on present and future trends, the market size is estimated from 2018 to 2030. Moreover, study also provides quantitative and qualitative analysis of each type to understand the driving factors for the fastest growing type segment for Alzheimers Disease Drug market.

Type of Alzheimers Disease Drug analyzed in this report are as follows:

• Centrally Acting AChE Inhibintors
• NMDA Antagonists

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Alzheimers Disease Drug Industry. Request a Free Sample PDF!

Application Segment Analysis of Alzheimers Disease Drug Market

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities for each application of Alzheimers Disease Drug from 2018 to 2030. This will also help to analyze the demand for Alzheimers Disease Drug across different end-use industries. Our research team will also help acquire additional data such as Value Chain, Patent analysis, Company Evaluation Quadrant (Matrix), and much more confidential analysis and data insights.

Some of the key Application of Alzheimers Disease Drug are:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

The above Graph is for representation purposes only. This chart does not depict actual Market share. Please purchase the Alzheimers Disease Drug market report 2023 Edition by contacting our team.

Alzheimers Disease Drug Type of Disease Segment Analysis

Late-onset Alzheimer's is the most common form of the disease, which happens to people ages 65 and older. Familial Alzheimer's disease is a form of Alzheimer's disease which is linked to genes. In families that are affected, members of at least two generations have had the disease. FAD makes up less than 1% of all cases of Alzheimer's.

• Early-Onset
• Late-Onset
• Familial

Alzheimers Disease Drug Drugs Type Segment Analysis

Cholinesterase inhibitors are most prescribed type of drugs to treat symptoms related to memory, thinking, language, judgment and other thought processes. These medications prevent the breakdown of acetylcholine, a chemical messenger important for memory and learning. These drugs support communication between nerve cells. Thus, it held the largest revenue share of over 57%.
In March 2022, the U.S. FDA approved the cholinesterase inhibitor Adlarity (donepezil hydrochloride) developed by Corium Inc., for the treatment of patients with severe dementia of Alzheimer’s disease (AD).

• Cholinesterase Inhibitors
• NMDA Receptor Antagonists

Alzheimers Disease Drug Product Segment Analysis

• Donepezil
• Galantamine
• Rivastigmine
• Memantine
• Others

Alzheimers Disease Drug End-Users Segment Analysis

Hospitals dominates the end-user segment of Alzheimer’s Disease Drug in year 2021. However, homecare will show high growth rate in near future as 90% of Americans ages 65 and older want to stay at home for as long as possible, and this age group is growing rapidly. Moreover, home healthcare companies allow people who require extra care no matter what their age to remain in their homes, reducing the burden otherwise shouldered by healthcare facilities, hospitals, assisted living or rehabilitation centres, and nursing homes.

• Hospitals
• Specialty Clinics
• Homecare

As per our analysis, market share for Alzheimer’s Disease Drug in North America is over 40%. Hence North America is dominating the market with USD XX Bn in 2021. High number of people in America shows symptoms for Alzheimer’s disease and this number is continuously increasing. Thus, demand for AD drugs is significant in North America. Further, U.S. Food and Drug Administration approved Aduhelm recently for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans.
Two years of COVID-19 pandemic have shifted the dynamics in the US healthcare value chain. Innovation and growth continued unabated in services. acceleration of value-based care models and increasing application of technology across the healthcare industry are likely to continue in the long term. All these parameters driven North America market for Alzheimer’s Disease Drug.
Asia-Pacific Alzheimer’s Disease Drug market is set to show significant growth rate in coming years
Asia-Pacific Alzheimer’s Disease Drug market is set to display growth at a high compound annual growth rate as countries/territories on multiple metrics, New Zealand, Australia, Hong Kong, and Japan along with China and India has high potential for healthcare sector. Growing population, and increasing awareness has stimulated growth for this market. Further, like U.S., China and Japan are also experiencing growth in its geriatric population.
Alzheimer’s Disease Drug is also seeing a rapid rise in popularity in Europe, partly due to an overall growth in the European geriatric population.

Region-wise, the market is analyzed across: (In case you wish to acquire a specific region or any country data then please contact us)

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!

• Majority of global manufacturers of Alzheimer’s Disease Drug are demonstrating world-class sustainable practices and are attracting a lot of capital. New product launches, pipeline products and R&D activities are some of the key strategies adopted by the key players to acquire a greater market share.
• The report involves complete profiling of below mentioned players which are identified among the top players. Numerous medicines for the symptomatic management of Alzheimer's disease are available in a fragmented market. Numerous suppliers are being forced to create new vaccinations due to the disease's high incidence and the demand for extremely effective therapies.

News

• September 2022

Eisai Co., Ltd. and Biogen Inc. completed the submission of Biologics License Application to U.S. Food and Drug Administration for lecanemab:
Eisai Co., Ltd. and Biogen Inc. announced that it has completed the rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) under the accelerated approval pathway for the investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab (BAN2401) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain.

• July 2021

AbbVie plans to move next-gen Aduhelm hopeful for Alzheimer's into the clinic
AbbVie has planned to push an Alzheimer’s disease candidate that potentially has a better safety profile into the clinic by year’s end or early next year. The company is pursuing a range of possible ways to tackle Alzheimer’s. Those include AL002, a monoclonal antibody trying to enhance the activity of the TREM2 gene, and AL003, which targets a genetic link to the disease, called sialic acid binding Ig-like lectin 3 (SIGLEC 3).

• November 2017

Novartis and Amgen have entered into collaboration with Banner Alzheimer's Institute
Novartis, Amgen and the Banner Alzheimer's Institute (BAI) has expanded collaboration in which the companies initiated a new trial - the Alzheimer's Prevention Initiative (API) Generation Study 2. This trial follows the launch of the Generation Study 1, and thus it determined whether the BACE1 inhibitor CNP520 can prevent or delay the onset of Alzheimer's disease symptoms in a high-risk population.

• November 2022

Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s disease
Roche announced results from the GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment (MCI) due to Alzheimer’s and mild Alzheimer’s dementia, collectively called early Alzheimer’s disease. Gantenerumab was well tolerated, including the subcutaneous administration.

Top Companies Market Share in Alzheimers Disease Drug Industry: (In no particular order of Rank)

• Eisai
• Pfizer
• Novartis
• Shire
• Janssen
• Forest Laboratories
• H. Lundbeck
• Merz
• Daiichi Sankyo
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables..